M. Oudkerk, S. Liu, M.A. Heuvelmans, J.E. Walter, J.K. Field, Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nat. Rev. Clin. Oncol. 18(3), 135–151 (2021)

Article  PubMed  Google Scholar 

R.S. Herbst, D. Morgensztern, C. Boshoff, The biology and management of non-small cell lung cancer. Nature. 553(7689), 446–454 (2018)

Article  CAS  PubMed  Google Scholar 

De D. Ruysscher, C. Faivre-Finn, K. Nackaerts, K. Jordan, J. Arends, J.Y. Douillard et al., Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann. Oncol. 31(1), 41–49 (2020)

Article  PubMed  Google Scholar 

S. Billan, O. Kaidar-Person, Z. Gil, Treatment after progression in the era of immunotherapy. Lancet Oncol. 21(10), e463–e476 (2020)

Article  CAS  PubMed  Google Scholar 

M. Massafra, M.I. Passalacqua, V. Gebbia, P. Macrì, C. Lazzari, V. Gregorc et al., Immunotherapeutic advances for NSCLC. Biologics. 15, 399–417 (2021)

PubMed  PubMed Central  Google Scholar 

G. Cannone, G.M. Comacchio, G. Pasello, E. Faccioli, M. Schiavon, A. Dell’Amore et al., Precision surgery in NSCLC. Cancers (Basel). 15(5), 1571 (2023)

Article  CAS  PubMed  Google Scholar 

M.L. Burr, C.E. Sparbier, K.L. Chan, Y.C. Chan, A. Kersbergen, E.Y.N. Lam et al., An evolutionarily conserved function of polycomb silences the MHC Class I Antigen Presentation Pathway and enables Immune Evasion in Cancer. Cancer Cell. 36(4), 385–401e8 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

N. McGranahan, R. Rosenthal, C.T. Hiley, A.J. Rowan, T.B.K. Watkins, G.A. Wilson et al., Allele-specific HLA loss and Immune escape in Lung Cancer Evolution. Cell. 171(6), 1259–1271e11 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D. Dersh, J. Hollý, J.W. Yewdell, A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21(2), 116–128 (2021)

Article  CAS  PubMed  Google Scholar 

G. Sari, K.L. Rock, Tumor immune evasion through loss of MHC class-I antigen presentation. Curr. Opin. Immunol. 83, 102329 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.L.M. Jongsma, J. Neefjes, R.M. Spaapen, Playing hide and seek: tumor cells in control of MHC class I antigen presentation. Mol. Immunol. 136, 36–44 (2021)

Article  CAS  PubMed  Google Scholar 

K. Qu, L.C. Zaba, A.T. Satpathy, P.G. Giresi, R. Li, Y. Jin et al., Chromatin Accessibility Landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell. 32(1), 27–41e4 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Wang, F. Hasan, A.C. Frey, H.S. Li, J. Park, K. Pan et al., Histone deacetylase inhibitors and IL21 cooperate to Reprogram Human Effector CD8 + T cells to memory T cells. Cancer Immunol. Res. 8(6), 794–805 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, R. Pazdur, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12(10), 1247–1252 (2007)

Article  CAS  PubMed  Google Scholar 

W. Yang, Y. Li, R. Gao, Z. Xiu, T. Sun, MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway. Oncogene. 39(5), 1098–1111 (2020)

Article  CAS  PubMed  Google Scholar 

N. Reguart, R. Rosell, F. Cardenal, A.F. Cardona, D. Isla, R. Palmero et al., Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. 84(2), 161–167 (2014)

Article  PubMed  Google Scholar 

T. Hoang, T.C. Campbell, C. Zhang, K. Kim, J.M. Kolesar, K.R. Oettel et al., Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest. New. Drugs. 32(1), 195–199 (2014)

Article  CAS  PubMed  Google Scholar 

K. Meissl, N. Simonović, L. Amenitsch, A. Witalisz-Siepracka, K. Klein, C. Lassnig et al., STAT1 isoforms differentially regulate NK Cell Maturation and Anti-tumor Activity. Front. Immunol. 11, 2189 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

X. Li, K. Pan, M. Vieth, M. Gerhard, W. Li, R. Mejías-Luque, JAK-STAT1 signaling pathway is an early response to Helicobacter pylori Infection and contributes to Immune escape and gastric carcinogenesis. Int. J. Mol. Sci. 23(8), 4147 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B.V. Park, Z.T. Freeman, A. Ghasemzadeh, M.A. Chattergoon, A. Rutebemberwa, J. Steigner et al., TGFβ1-Mediated SMAD3 enhances PD-1 expression on Antigen-Specific T cells in Cancer. Cancer Discov. 6(12), 1366–1381 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

I. Kashiwagi, R. Morita, T. Schichita, K. Komai, K. Saeki, M. Matsumoto et al., Smad2 and Smad3 inversely regulate TGF-β autoinduction in Clostridium butyricum-activated dendritic cells. Immunity. 43(1), 65–79 (2015)

Article  CAS  PubMed  Google Scholar 

Y. Liu, L. Xu, Y. Jiang, J. Sun, X. He, Phenotypic and functional analysis of LCMV gp33-41-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells. Cell. Mol. Immunol. 4(6), 431–437 (2007)

CAS  PubMed  Google Scholar 

A.A. Mehrizi, N. Rezvani, S. Zakeri, A. Gholami, L. Babaeekhou, Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium Falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice. Med. Microbiol. Immunol. 207(2), 151–166 (2018)

Article  CAS  PubMed  Google Scholar 

A.M. Cornel, E. Dunnebach, D.A. Hofman, S. Das, S. Sengupta, van den F. Ham et al., Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J. Immunother Cancer. 10(12), e005002 (2022)

Article  PubMed  PubMed Central  Google Scholar 

X. Wu, T. Li, R. Jiang, X. Yang, H. Guo, R. Yang, Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer. 22(1), 194 (2023)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Jiang, Y. Li, M. Shen, Y. Liang, Y. Qian, H. Dai et al., Interferon-α promotes MHC I antigen presentation of islet β cells through STAT1-IRF7 pathway in type 1 diabetes. Immunology. 166(2), 210–221 (2022)

Article  CAS  PubMed  Google Scholar 

J. Tur, C. Farrera, E. Sánchez-Tilló, T. Vico, P. Guerrero-Gonzalez, A. Fernandez-Elorduy et al., Induction of CIITA by IFN-γ in macrophages involves STAT1 activation by JAK and JNK. Immunobiology. 226(5), 152114 (2021)

Article  CAS  PubMed  Google Scholar 

C. Schelker, P. Nowak-Sliwinska, G. Borchard, HDACIs and TKIs combinations and their liposomal delivery for cancer treatment. J. Control Release. 358, 59–77 (2023)

Article  CAS  PubMed  Google Scholar 

J.E. Jr Darnell, I.M. Kerr, G.R. Stark, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264, 1415–1421 (1994)

Article  CAS  PubMed  Google Scholar 

E.H. Ervin, R. French, C.H. Chang, S. Pauklin, Inside the stemness engine: mechanistic links between deregulated transcription fac